Zura Bio Limited (NASDAQ:ZURA) Stock Has Average Price Target of $17.00

Zura Bio Limited (NASDAQ:ZURA) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $17.00.

ZURA has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, October 2nd. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Wedbush boosted their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. William Blair initiated coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They issued an “outperform” rating on the stock. Finally, Guggenheim increased their target price on Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th.

Zura Bio Trading Down 1.0%

Shares of ZURA opened at $4.13 on Tuesday. The firm has a market cap of $395.77 million, a PE ratio of -3.65 and a beta of 0.01. Zura Bio has a 1-year low of $3.15 and a 1-year high of $7.44. The firm has a fifty day simple moving average of $5.22 and a two-hundred day simple moving average of $5.05.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. As a group, research analysts forecast that Zura Bio will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Commodore Capital LP bought a new position in Zura Bio during the 1st quarter valued at about $19,338,000. Siren L.L.C. grew its stake in shares of Zura Bio by 187.3% during the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after buying an additional 2,434,866 shares during the last quarter. EcoR1 Capital LLC bought a new position in Zura Bio in the 1st quarter valued at $7,019,000. Stempoint Capital LP purchased a new position in Zura Bio in the 1st quarter worth about $4,483,000. Finally, Affinity Asset Advisors LLC increased its position in shares of Zura Bio by 41.4% during the first quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company’s stock worth $15,258,000 after acquiring an additional 750,632 shares during the period. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on developing medicines for chronic immune-mediated diseases. The company’s research programs are designed to address conditions in which abnormal immune responses contribute to inflammation and tissue damage.

Zura Bio is advancing a pipeline of investigational antibody-based therapies for diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and systemic sclerosis. Its programs target biological pathways involved in inflammation, with the goal of developing treatments for patients who may not respond adequately to existing therapies.